14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $0.87 $1.65 Monday, 22nd Apr 2024 ADAP stock ended at $1.01. This is 3.41% more than the trading day before Friday, 19th Apr 2024. During the day the stock fluctuated 13.34% from a day low at $0.95 to a day high of $1.08.
90 days $0.691 $2.05
52 weeks $0.420 $2.05

Historical Adaptimmune Therapeutics plc prices

Date Open High Low Close Volume
Mar 15, 2024 $1.47 $1.49 $1.42 $1.48 630 710
Mar 14, 2024 $1.55 $1.56 $1.41 $1.46 1 336 801
Mar 13, 2024 $1.56 $1.70 $1.48 $1.59 1 395 812
Mar 12, 2024 $1.54 $1.55 $1.42 $1.49 1 610 959
Mar 11, 2024 $1.80 $1.80 $1.53 $1.54 2 086 121
Mar 08, 2024 $1.79 $2.05 $1.72 $1.75 11 995 713
Mar 07, 2024 $1.75 $1.85 $1.62 $1.74 2 524 115
Mar 06, 2024 $1.59 $1.75 $1.49 $1.71 2 202 397
Mar 05, 2024 $1.48 $1.53 $1.38 $1.46 813 347
Mar 04, 2024 $1.63 $1.64 $1.42 $1.48 1 116 993
Mar 01, 2024 $1.56 $1.64 $1.55 $1.59 920 841
Feb 29, 2024 $1.61 $1.61 $1.51 $1.57 1 532 994
Feb 28, 2024 $1.77 $1.77 $1.50 $1.61 1 707 842
Feb 27, 2024 $1.69 $1.79 $1.60 $1.71 2 182 338
Feb 26, 2024 $1.50 $1.64 $1.43 $1.64 1 659 015
Feb 23, 2024 $1.45 $1.50 $1.38 $1.48 807 851
Feb 22, 2024 $1.53 $1.64 $1.38 $1.38 1 976 169
Feb 21, 2024 $1.23 $1.57 $1.23 $1.50 2 809 572
Feb 20, 2024 $1.18 $1.32 $1.18 $1.26 1 085 016
Feb 16, 2024 $1.25 $1.28 $1.18 $1.20 786 588
Feb 15, 2024 $1.32 $1.32 $1.22 $1.25 667 398
Feb 14, 2024 $1.25 $1.32 $1.20 $1.28 732 073
Feb 13, 2024 $1.16 $1.29 $1.15 $1.20 1 061 027
Feb 12, 2024 $1.26 $1.28 $1.19 $1.21 1 088 100
Feb 09, 2024 $1.24 $1.33 $1.20 $1.25 1 484 063
Click to get the best stock tips daily for free!

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposa... ADAP Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT